Natco Pharma receives USFDA approval for Nitroglycerin Sublingual Tablet

Natco Pharma has received final ANDA nod from USFDA for chest pain tablets through its marketing partner Alvogen. The drug Nitroglycerin Sublingual Tablets in strengths of USP, 0.3 mg, 0.4 mg, and 0.6 mg are used to treat episodes of angina (chest pain) in people who have coronary artery disease (narrowing of the blood vessels that supply blood to the heart).

According to market estimates, Nitroglycerin Sublingual Tablets had total annual sales of around USD 77.3 million in the US market, for the year ending 2018.

Company Profile : Natco Pharma Ltd

Be the first to comment

Leave a Reply

Your email address will not be published.